Findings suggesting inflammation-induced activation of SMO to degrade SPM and produce acrolein include increased acrolein levels in renal failure [35], cerebrovascular disease [36], and other age-related conditions that have been reported to have adverse health effects [37]. This evidence concerns the gene SMO and kidney failure.